SCHEMBL23834841

SCHEMBL23834841

COC(=O)c1ccc(OC)c(F)c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
HPGDS O60760 1/20 0.41
KMT2A Q03164 2/20 0.40
SOS1 Q07889 1/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
HSP90AA1 P07900 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MYC P01106 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GAA P10253 2/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK4 Q16654 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463232 0.84 KDM4E (0.46) KDM4EKMT2AMAPTHTTMYC
SCHEMBL20714700 0.82 CES2 (0.48) KDM4ESOS1MAPTNPSR1MYC
SCHEMBL23835507 0.82 GRM2 (0.42) KDM4ESOS1MAPTHTTHSP90AA1
SCHEMBL23848001 0.82 GRM2 (0.42) KDM4EKMT2AMAPTHTTHSP90AA1
SCHEMBL27605516 0.81 HMGCR (0.47) KDM4EHPGDSKMT2ACA9ALDH1A1
SCHEMBL23578354 0.81 CA12 (0.49) KDM4ESOS1MAPTMYCHSD17B10
SCHEMBL21828895 0.81 MAPT (0.50) KDM4EKMT2AMAPTMYCHSD17B10
SCHEMBL26660999 0.81 MAPT (0.50) KDM4EMAPTNPSR1HSD17B10GAA
SCHEMBL27433079 0.81 MYC (0.44) KDM4EKMT2AMAPTHTTHSP90AA1
SCHEMBL23848002 0.79 GRM2 (0.41) SOS1MAPTHTTHSP90AA1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 EP disclosed
CN-119241481-A Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2025-01-03 CN disclosed
US-20240382600-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER NOVARTIS AG (CH) 2024-11-21 US disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
CN-115298170-B Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2024-09-27 CN disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed
EP-4395828-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER Novartis AG (CH) 2024-07-10 EP disclosed
WO-2023031801-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER NOVARTIS AG (CH) 2023-03-09 WO disclosed
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP disclosed
CN-115298170-A Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions 诺华股份有限公司 2022-11-04 CN disclosed
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2021-09-30 US disclosed
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2021-09-30 US disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382600-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER YAP1, JMJD7, TOR1AIP1 KDM4E 1085/4885HPGDS 2645/4885KMT2A 1294/4885
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 KDM4E 1512/4885HPGDS 2821/4885KMT2A 1716/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 KDM4E 1512/4885HPGDS 2821/4885KMT2A 1716/4885
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 KDM4E 1523/4885HPGDS 2852/4885KMT2A 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.